{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ankylosing-spondylitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 73205670-de2a-42af-9a9f-a5add41de059 --><h2>Changes</h2><!-- end field 73205670-de2a-42af-9a9f-a5add41de059 -->","summary":null,"htmlStringContent":"<!-- begin item cc9b69e3-efd1-4dd2-b80b-fc6c2d8d1bdb --><!-- begin field 271047a0-138e-4f6f-8fd4-45b2ec0de092 --><p><strong>May 2019 </strong>— reviewed. A literature search was conducted in April 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. Recommendations have been updated in line with the 2017 National Institute for Health and Care Excellence (NICE) guideline <em>Spondyloarthritis in over 16s: diagnosis and management, </em>and the definition section has been updated to clarify the terminology of axial spondyloarthritis, ankylosing spondylitis (radiographic axial spondyloarthritis), and non-radiographic axial spondyloarthritis. The section on advice for people with suspected ankylosing spondylitis has been tailored to people without a confirmed diagnosis, and a new advice section has been added to the scenario on confirmed ankylosing spondylitis. The previous section on assessment of confirmed ankylosing spondylitis has been incorporated into the follow-up section.</p><!-- end field 271047a0-138e-4f6f-8fd4-45b2ec0de092 --><!-- end item cc9b69e3-efd1-4dd2-b80b-fc6c2d8d1bdb -->","topic":{"id":"228aa309-0970-5ae0-a937-1a670214e066","topicId":"0752afda-bf5b-48c4-b4af-e842f0a9b229","topicName":"Ankylosing spondylitis","slug":"ankylosing-spondylitis","lastRevised":"Last revised in May 2019","chapters":[{"id":"1318829b-e445-59f5-8079-ced63414cf7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28658e82-53d5-5798-84bf-7e67cc233b06","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes"},{"id":"ecb29915-59e9-5752-9bbb-fc44515688b3","slug":"update","fullItemName":"Update"}]},{"id":"81161324-4d7b-5419-85a9-dae9f57fa83b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c127b8df-f565-5637-adb8-bafbfd767c40","slug":"goals","fullItemName":"Goals"},{"id":"091c0d27-63a5-548e-8f08-5bfb48e416a7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9ca120c-2183-5429-9706-101fc20540e1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58752ac1-77db-5b74-8e2e-bf0081dd74fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ffa55c0b-7b3d-583c-8a67-f0372230cbf9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4c33c07f-65b3-572b-b4c0-1eecffd16191","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8c9e7d3f-07eb-5b06-9f42-67f6c18e4ce2","slug":"definition","fullItemName":"Definition"},{"id":"64b026f5-a69f-5ef8-800d-7aee9ac65509","slug":"causes","fullItemName":"Causes"},{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications"},{"id":"76129f0b-5489-511d-bc1d-565b990f4fb8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a54d37d1-407b-50c4-b5e8-c98891ee1e00","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6a2b7eca-b47b-5a11-9909-91a6aea6835a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ea0d0799-6976-5240-92c5-4623f9074fda","slug":"investigations","fullItemName":"Investigations"},{"id":"58c6e66c-a8a5-56c9-8c47-7127807d9c73","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis"},{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis"}]},{"id":"b82cc559-18dd-500a-add0-dde6d8b59e63","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"76b292a6-865e-5dcd-9885-3e235e7664a4","slug":"oral-nsaids","fullItemName":"Oral NSAIDs"},{"id":"113dcc0f-4841-54a0-9101-a64009316e7c","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"52667269-49b0-5132-839c-67d58b9480db","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"}]},{"id":"59c2b871-f61e-5fb4-a894-cae5bdeda4bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"80288a50-5bef-5779-8bf9-7d8abf169080","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"932977c5-3d44-5c3b-8787-7de309af3820","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"eb5fa8b8-2845-567c-ab0a-2274329dfc51","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4153414-1fd0-5779-a348-78ee4ab85730","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12b49dd2-6a18-5e19-8960-15901b6a91b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1e8ec-8cac-5c4a-ac1b-758b9b2501bb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67d800ae-fb2a-559a-89de-a4813d740021","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"66c5832b-8e3a-556b-af4c-6770b949b0b2","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field e1bc1451-be30-497e-89a5-d566aece1b54 --><h3>Previous changes</h3><!-- end field e1bc1451-be30-497e-89a5-d566aece1b54 -->","summary":null,"htmlStringContent":"<!-- begin item cb2146bc-05eb-48c4-8f39-954072d34e06 --><!-- begin field 020d8555-2129-46be-b727-edcf9534949c --><p><strong>February 2013 </strong>— reviewed. A literature search was conducted in December 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. Changes have been made to the sections on diagnosis and referral.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2012 </strong>— minor update. Information from the manufacturer's Summary of Product Characteristics about the possible interaction between pantoprazole and warfarin has been added to drug interactions. Information from the British National Formulary about the potentially serious interaction between proton pump inhibitors and protease inhibitors (atazanavir and saquinavir) has also been added. Issued in January 2012.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>June 2010 </strong>— minor update. In people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line NSAIDs. Issued in July 2010.</p><p><strong>July 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and proton pump inhibitors. Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential. Issued in July 2009.</p><p><strong>June 2009 </strong>— minor update. The intra-articular corticosteroid prescriptions have been updated. Issued in June 2009.</p><p><strong>March to July 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p>There are no major changes to the recommendations on managing ankylosing spondylitis. However, there are some changes in the recommendations on the use of nonsteroidal anti-inflammatory drugs (NSAIDs), with clearer advice on balancing the benefits and risks of treatment.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>April 2005 </strong>— reviewed. Validated in June 2005 and issued in July 2005.</p><p><strong>June 2001 </strong>— reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>July 1999 </strong>— written. Validated in October 1999 and issued in January 2000.</p><!-- end field 020d8555-2129-46be-b727-edcf9534949c --><!-- end item cb2146bc-05eb-48c4-8f39-954072d34e06 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}